Status: Recruiting
Vancomycin in Primary Sclerosing Cholangitis in Italy
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications. This is a Phase 2 randomized, double bind, placebo-controlled, monocentric study evaluating the safety and efficacy of two doses of oral vancomycin (i.e. 750 mg and 1500 mg/day) in subject between 15 - 70 years old with PSC.
Participants needed: 84
Trial details
Phase: Phase 2Age: 15-70Biological sex: AllType: InterventionalSponsor: University of Milano BicoccaUpdated: Jul 25, 2025Locations: 1
Eligibility criteria
Willing and able to give informed consent prior to any study specific procedure... [+10]
Receiving an antibiotic or probiotic within 3 months prior to the study; [+21]